Sign up to access all our data and the evidence and analysis underlying our overall scores. Once you've created an account, we'll get in touch with further details:
Sign Up
| Overall Assessment |
Analysis |
Score |
|
None
|
Zydus Lifesciences Ltd discloses its contributions to trade associations for FY 2023-24, reporting “Trade associations or tax-exempt groups (e.g. think tanks) 98,18,800” and itemizing payments to bodies such as the Indian Pharmaceutical Alliance and FICCI, yet the company does not disclose any internal policy, oversight body, or review process for its lobbying activities, no named individual or committee responsible for ensuring alignment of advocacy with corporate objectives or climate goals, and no mechanisms for monitoring or managing either its direct or indirect lobbying efforts. We found no evidence of a formal lobbying governance framework in its disclosures.
View Sources
|
E
|
| Overall Assessment |
Analysis |
Score |
|
Limited
|
Zydus Lifesciences Ltd provides only limited insight into its climate-related lobbying. The company reports that it channels advocacy through trade bodies such as the Indian Pharmaceutical Alliance and FICCI and discloses the value of its financial contribution, indicating an indirect lobbying mechanism, but it does not explain how it engages (for example, letters, meetings, or consultations) or identify any specific government bodies or officials it seeks to influence. Its disclosure does not name any particular climate or energy transition policies, laws, or regulations it has addressed; instead, it refers broadly to supporting sustainable development and industry growth. Similarly, it outlines no concrete policy changes or legislative outcomes it seeks, beyond this general aspiration. Consequently, while the company acknowledges some participation in policy advocacy, the absence of detail on the climate policies involved, the mechanisms employed, and the specific outcomes desired leaves most aspects of its climate lobbying largely untransparent.
|
D
|